Successful Treatment of Pediatric Epstein-Barr Virus-positive Aggressive Natural Killer-Cell Leukemia

Bo Kyung Kim, Kyung Taek Hong, Hyoung Jin Kang, Hong Yul An, Jung Yoon Choi, Che Ry Hong, Kyung Duk Park, Dong Soon Lee, Hee Young Shin

Research output: Contribution to journalArticle


Epstein-Barr virus (EBV)-positive aggressive natural killer-cell leukemia (ANKL) is a rare malignancy of mature natural killer cells, with a very poor survival rate. Patients have a rapidly declining clinical course and a poor prognosis, with a median survival of only a few months. Herein, we describe a 16-year-old boy who was diagnosed with EBV-positive ANKL and successfully treated using combination chemotherapy and a subsequent allogeneic hematopoietic stem cell transplantation (alloHSCT). The patient is disease free 4 years and 9 months after alloHSCT. Thus, combination chemotherapy followed by alloHSCT seems to be a promising therapeutic option for EBV-positive ANKL.

Original languageEnglish
Pages (from-to)e336-e337
JournalJournal of Pediatric Hematology/Oncology
Issue number5
StatePublished - 1 Jul 2019


  • Epstein-Barr virus
  • aggressive NK cell leukemia
  • allogeneic hematopoietic stem cell transplantation

Cite this